Actively Recruiting
Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke
Led by Universitätsklinikum Hamburg-Eppendorf · Updated on 2026-05-07
100
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to * to investigate the prevalence and time course of autonomic dysfunction in acute ischemic stroke patients; * to evaluate the influence of lesion location on autonomic dysfunction; * to identify patterns of structural and functional brain connectivity within the central autonomic control circuits associated with autonomic dysfunction; and * to explore causal models of the link between brain lesions; cardiac, immunological and endocrine biomarkers; and dysautonomia. Researchers will compare patients with acute ischemic stroke to patients with transient ischemic attacks to study the effect of acute ischemic brain lesions. Participants will * undergo cardiovascular autonomic function testing; * receive structural and functional MR imaging; * provide blood samples for determinaton of serological biomarkers auf dysautonomia.
CONDITIONS
Official Title
Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of either acute ischemic stroke with an ischemic lesion visible on CT/MRI or persistent focal deficits 24 hours after symptom onset, or transient ischemic attack with transient clinical deficits including motor or speech disturbance and not limited to isolated vertigo/dizziness, visual disturbance, or sensory disturbance
- Symptom onset within 72 hours prior to hospital admission
- Ability to walk without help from another person before stroke or TIA (modified Rankin scale score less than 4)
- Age over 18 years
- Informed consent by the patient or a legal representative (including a spouse)
You will not qualify if you...
- Stroke occurring during hospital stay
- Contraindications to MRI (e.g., claustrophobia, pregnancy, pacemakers, implants)
- Known moderate to severe dementia
- Previous structural brain damage except leukoaraiosis due to cerebral small vessel disease
- Significant narrowing of the common or internal carotid artery affecting blood flow
- Left heart failure with estimated left ventricular ejection fraction less than 50%
- Other systemic illnesses that can cause autonomic dysfunction such as active infection, thyroid disease, or neurodegenerative disorders like Parkinson's disease or multiple system atrophy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, Germany, 20246
Actively Recruiting
Research Team
E
Eckhard Schlemm
CONTACT
T
Thies Ingwersen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here